Localized lipodystrophy
Methodology & AI Transparency ⓘ
Localized lipodystrophy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as E88.13, Localized lipodystrophy falls under Weight & Metabolism management, where hepatic steatosis screening in Localized lipodystrophy (E88.13: (FIB-4)) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Localized lipodystrophy uses ICD-10 E88.13 across Weight & Metabolism specialty care.
- 3 Typical cash cost range: Differential triage of Localized lipodystrophy (E88.13) utilizes hepatic steatosis screening in Localized lipodystrophy (E88.13: (FIB-4)).
- 4 Top reported side effects / signs: Follow-up benchmark in Localized lipodystrophy: maintaining DEXA Visceral Adipose in Localized lipodystrophy (E88.13: Tissue (VAT)) within < 1.0 lb (< 100 cm2) (E88.13).
Ask our AI Specialists anything about Localized lipodystrophy
What Is Localized lipodystrophy?
Designated in federal medical registries as E88.13, Localized lipodystrophy falls under Weight & Metabolism management, where hepatic steatosis screening in Localized lipodystrophy (E88.13: (FIB-4)) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Localized lipodystrophy (E88.13) features adaptive thermogenic slowing [Localized lipodystrophy E88.13]. therapeutic stabilization in weight & metabolism is verified against Waist-to-Height Ratio [Localized lipodystrophy E88.13].
Common Symptoms & Clinical Signs
- • Presentation of Localized lipodystrophy (E88.13): joint load discomfort in Localized lipodystrophy (E88.13: in knees, hips,)
- • Secondary Localized lipodystrophy clinical sign: daytime sluggishness or in Localized lipodystrophy (E88.13: loud snoring linked)
- • Symptom flares in Localized lipodystrophy correlating with DEXA Visceral Adipose in Localized lipodystrophy (E88.13: Tissue (VAT)) deviation outside < 1.0 lb (< 100 cm2) (E88.13)
- • Functional weight & metabolism impact requiring hepatic steatosis screening in Localized lipodystrophy (E88.13: (FIB-4)) evaluation (E88.13)
Localized lipodystrophy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.13 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Localized lipodystrophy (E88.13: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E88.13) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Localized lipodystrophy E88.13] | < 0.50 (E88.13) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Localized lipodystrophy (E88.13: Index) | < 1.4 (E88.13) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Localized lipodystrophy
Treatment selection for Localized lipodystrophy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Localized lipodystrophy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on GLP-1 receptor agonists for weight: What a 7,024-Participant Study Found GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated. Medicine • 2026-03-13 • Meta-Analysis | N = 7,024 | 99/100 | PMID 41824845 ↗ |
| New Insights on Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post: What a 1,775-Participant Study Found In this post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials, tirzepatide-treated participants with obesity or overweight in both ER and non-ER groups achieved clinically meaningful weight reduction and improvements in... Diabetes, obesity & metabolism • 2026-09-15 • Phase III Randomized Trial | N = 1,775 | 96/100 | PMID 42348366 ↗ |
| What the Latest Evidence Really Says About GLP1-RA in Optimizing Weight Loss Post-Bariatric By systematically reviewing and analyzing data from three randomized controlled trials (RCTs) involving 130 patients, we found that GLP1-RA therapy, particularly liraglutide (1.8-3 mg), significantly reduced mean BMI and body... Obesity surgery • 2024-10-15 • Meta-Analysis | N = 130 | 92/100 | PMID 39215779 ↗ |
| New Insights on Quality of Life Implications of Dose-Escalated External Beam Radiation for: What a 1,532-Participant Study Found Compliance with PRO data collection was lower than anticipated in this phase 3 trial. International journal of radiation oncology, biology, physics • 2022-01-01 • Phase III Randomized Trial | N = 1,532 | 90/100 | PMID 34919884 ↗ |
| Can This Approach Help? Inside the Latest Research on RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized Tislelizumab is an anti-PD-1 antibody specifically engineered to minimize FcɣR binding on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. Future oncology (London, England) • 2021-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34269067 ↗ |
Localized lipodystrophy Patient Community & “People Like Me” Threads
Filter Localized lipodystrophy community threads and patient logs by age, biological sex, dosage, and treatment duration.